News Article

Vespa Capital invests in Bluecrest Health

25 July 2019

Candesic is proud to have provided the commercial due diligence and strategic guidance that resulted in the 17M GBP investment in Bluecrest by Vespa Capital. Bluecrest Health Screening offers checks for common diseases that are often diagnosed too late.  We fulfil our core mission by providing outstanding advice for companies that work to make us healthier and happier.

Candesic also works in services hospitals medical communications, CRO, POC, Healthcare IT and many more topics in both UK and global health care and life sciences.

“Candesic’s in depth understanding of both primary care and preventative healthcare helped us to assess the health screening market and Bluecrest’s position within it.  In addition, their broader healthcare experience has provided the business with useful insight into potential growth opportunities outside of management’s existing plans.”
– David Forbes, Director, Vespa Capital

“Having the Candesic team as part of the process that led to a fantastic investment in Bluecrest was a perfect fit.  Their knowledge of healthcare and innovative strategic thinking not only supported the deal but also our own plans for the future.  We look forward to working with Candesic again.”
– Peter Blencowe, Managing Director, Bluecrest